Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:18 PM
Ignite Modification Date:
2025-12-24 @ 1:18 PM
NCT ID:
NCT05266495
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of nAMD
* Patients with ≥18 years of age at index
* Receipt of at least one injection of brolucizumab (not necessarily the first one) during the index period
* Signed informed consent
Exclusion Criteria:
* Patients treated for retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and have diagnoses of diabetes-related macular degeneration within 6 months prior to the index date
* Receipt of any anti-VEGF treatment other than brolucizumab in the study eye during the index period
* Receipt of brolucizumab in the study eye more than 6 months before the index period, i.e., brolucizumab treatment started more than 6 months before the start of the study
* Any active intraocular or periocular infection or active intraocular inflammation in the study eye at index date
* Patients who have any contraindication and are not eligible for treatment with brolucizumab as according to the label
* Patients who were treated with more than 2 types of anti-VEGF before index date (4th line brolucizumab patients or more)
* Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 12-month study participation
* Patients participating in parallel in an interventional clinical trial Note: if a patient experiences an adverse event (AE), they may still be recruited in another study following this AE if they fulfill their inclusion criteria. Their data will still be collected as planned by the current protocol
* Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT05266495
Study Brief:
Protocol Section:
NCT05266495